AA | Saturday, April 17, 2021 – 15:24 | Last Updated: 17 04 2021 – 15:24
Industry and Technology Minister Mustafa Varank, Turkey Scientific and Technological Research Council of Turkey (TUBITAK) Covidien-19 Turkey Platform based on the work of the period of the virus-like particles under the roof (VLP) vaccine to participate in the Phase 1 stage of human trials were under observation at Ankara Oncology Hospital.
According to the written statement made by the Ministry; Minister Varank and TÜBİTAK President Prof. Dr. Hasan Mandal came to Ankara Oncology Hospital Phase 1 Clinical Research Center in the morning. Minister Varanka Ankara Oncology Training and Research Hospital Chief Physician Prof. Dr. Fevzi Altuntaş and Clinical Research Center Coordinator Assoc. Dr. Halil Kara was accompanied. Minister Varanka, whose blood tests and clinical parameters including ECG are monitored, stated that the first dose of vaccine will be administered in the evening. Varank, who will spend the night in the hospital, is expected to be discharged tomorrow. Unlike vaccines VLP vaccine which was introduced in Turkey, not to be under the skin into the muscle from the arm by subcutaneous injection method. Minister Varank will receive the second dose of vaccine after 21 days.
36 PEOPLE PARTICIPATE IN HUMAN TRIALS
Prof. Dr. The human trials of the VLP vaccine candidate, developed as a result of the joint project of Mayda Gürsel and the couple from Bilkent University İhsan Gürsel, will be applied to two groups of 18 people, one low and one high dose. Six of both groups will consist of placebo, i.e. injections containing no active or active ingredients. The names of the volunteers, except for Minister Varank and TÜBİTAK President Mandal, are kept confidential. Health personnel who will administer the vaccine cannot have information about the content of the injection in the person being administered.
‘PREPARED FOR BRITISH VARIANT’
The innovative vaccine candidate of the Gürsel couple is expected to move to Phase 2 in June and Phase 3 in August. The Phase 2 study of the native VLP vaccine candidate was prepared according to the British variant. In VLP type vaccines, the developed virus-like particles mimic the virus in a way that does not cause infection. While these particles induce an immune response, they do not cause illness. Another feature of the vaccine candidate developed by the Gürsel couple is that, unlike other VLP vaccines, this platform uses 4 structural proteins of the virus as vaccine antigens. In this respect, there is no vaccine candidate entering the phase of clinical human trials in the world.
ANNOUNCEMENT IN THE WORLD, ONE IN TURKEY
World No. TÜBİTAK Covidien-19 Turkey Platform covered by the vaccine candidate developed with a single VLP technology was the clinical stage of the 4th vaccine candidate in this kind in the world taking part in the World Health Organization Covidien-19 vaccine candidate list on March 30. Varank visited Nobel İlaç’s Biotechnological Medicine Facility in Gebze TÜBİTAK Marmara Technopolis in order to see the work of Mayda and İhsan Gürsel on site.